In this episode of MedCity Pivot podcast, we talk with Camille Hertzka, AstraZeneca's U.S. Head of Medical Affairs Oncology, about the clinical study findings on lung cancer presented at ESMO and the rapidly changing landscape for lung cancer treatment.
Sotorasib, a KRAS G12C inhibitor, showed an overall response rate and duration of response that analysts called approvable, but they noted the results have waned over time, and combinations may be the way forward.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The biotech company presented data for AMG 510 at the European Society for Medical Oncology during the weekend. Although the drug showed activity, the data got mixed reactions from investment bank analysts.
The company announced the presentation of data at the ESMO meeting in Barcelona for Tibsovo, in patients with IDH1-mutant bile duct cancer. The drug is approved for treating IDH1-mutation positive acute myeloid leukemia.
The company pointed to better survival numbers in patients with high tumor mutational burden, in a presentation at the ESMO immuno-oncology congress in Geneva.